Investor
BoxGroupCheck size: BoxGroup publicly invests up to $1M. Third-party profiles estimate Disha's range at $500K–$1M, but no primary source confirms a personal range, so the firm ceiling is the safer planning assumption.
Disha invests at the earliest stages with a differentiated mix of finance, neuroscience, biotech R&D, and prior growth-investing exposure. Her public investor profile points to AI, enterprise infrastructure and software, digital and consumer health, biotech, and commerce. Within BoxGroup's generalist model, the through-line is an exceptional founder using technical or domain insight to create a category, not a rigid sector checklist.
Technically or scientifically credible founders, authentic founder-market fit, ambitious visions, strong product velocity, and a sharp insight about a customer or system that incumbents miss. Her cross-disciplinary background is particularly relevant when technical depth must translate into a usable product.
No personal pass list is public. Likely weaker fits include science without a product or commercialization path, AI without defensibility or measurable workflow benefit, teams without domain credibility, and later-stage raises outside BoxGroup's formation-stage focus.
Open with the non-obvious technical or customer insight and why this team is equipped to act on it. For AI, show evals, proprietary workflow or data advantage, and user outcomes; for health or biotech, cover evidence quality, regulatory and reimbursement paths, development milestones, and commercialization. Keep the story formation-stage honest and make the next de-risking milestone explicit.
Evaluate both technical validity and the path from a scientific advantage to a product users adopt, including regulatory, operational, and distribution constraints.
Test whether an AI product improves a complete customer workflow with measurable accuracy, speed, or cost—not simply whether it demonstrates model capability.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Disha has been an Investor at BoxGroup since 2023. She previously invested at Accel and worked as an R&D scientist in Allogene Therapeutics' solid-tumor CAR-T group, with earlier research experience at Celularity. She earned a BS in Economics from Wharton and a BA in Neuroscience from the University of Pennsylvania.